Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01158157 · ClinicalTrials.gov registry record · Phase 3
VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV
A Phase 3 study of Smallpox Vaccine Adverse Reaction, sponsored by Emergent BioSolutions.
- Completed
- Registry status
- Phase 3
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT01158157: Completed Phase 3 study of Smallpox Vaccine Adverse Reaction, sponsored by Emergent BioSolutions.
NCT01158157 is a Phase 3 study of Smallpox Vaccine Adverse Reaction that has completed, run by Emergent BioSolutions. The registered enrollment target is 25 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01158157, a Phase 3 study of Smallpox Vaccine Adverse Reaction, has completed, sponsored by Emergent BioSolutions.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to vaccinate plasma donors with ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).
Conditions Studied
Interventions
- BIOLOGICAL ACAM2000
Study Locations (1)
Florida
- Cangene Plasma Resources, Mid-Florida - Altamonte Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-09-13 |
| Est. Completion | 2012-02-14 |
| Phase | Phase 3 |
What the finished NCT01158157 record still lists
NCT01158157 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Smallpox Vaccine Adverse Reaction appearing as the primary indexed condition, and to 1 intervention - of which ACAM2000 is the first listed.
NCT01158157 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT01158157 about?
NCT01158157 is a clinical study titled "VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV". The purpose of this study is to vaccinate plasma donors with ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).
What is the current status of trial NCT01158157?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 25 participants. The study started on 2010-09-13. Estimated completion is 2012-02-14.
What conditions does trial NCT01158157 study?
This clinical trial studies the following conditions: Smallpox Vaccine Adverse Reaction.
What interventions are being tested in trial NCT01158157?
The interventions under investigation include: ACAM2000 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01158157?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01158157 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01158157's enrollment target sits among peer trials
25 1941st of 2000 higher than 58 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI